First Manhattan’s NeuBase Therapeutics, Inc. Common Stock NBSE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-353
| Closed | -$158 | – | 1396 |
|
|
2024
Q1 | $158 | Hold |
353
| – | – | ﹤0.01% | 1382 |
|
|
2023
Q4 | $261 | Sell |
353
-353
| -50% | -$257 | ﹤0.01% | 1388 |
|
|
2023
Q3 | $614 | Hold |
706
| – | – | ﹤0.01% | 1365 |
|
|
2023
Q2 | $1.32K | Hold |
706
| – | – | ﹤0.01% | 1322 |
|
|
2023
Q1 | $2.61K | Hold |
706
| – | – | ﹤0.01% | 1363 |
|
|
2022
Q4 | $2.69K | Hold |
706
| – | – | ﹤0.01% | 1515 |
|
|
2022
Q3 | $5K | Hold |
706
| – | – | ﹤0.01% | 1324 |
|
|
2022
Q2 | $14K | Hold |
706
| – | – | ﹤0.01% | 1185 |
|
|
2022
Q1 | $26K | Buy |
+706
| New | +$24.4K | ﹤0.01% | 1118 |
|
|
2019
Q4 | – | Sell |
-18
| Closed | -$1K | – | 1389 |
|
|
2019
Q3 | $1K | Hold |
18
| – | – | ﹤0.01% | 1305 |
|
|
2019
Q2 | $1K | Hold |
18
| – | – | ﹤0.01% | 1346 |
|
|
2019
Q1 | $0 | Hold |
18
| – | – | ﹤0.01% | 1472 |
|
|
2018
Q4 | $0 | Hold |
18
| – | – | ﹤0.01% | 1453 |
|
|
2018
Q3 | $1K | Hold |
18
| – | – | ﹤0.01% | 1377 |
|
|
2018
Q2 | $1K | Hold |
18
| – | – | ﹤0.01% | 1333 |
|
|
2018
Q1 | $1K | Hold |
18
| – | – | ﹤0.01% | 1356 |
|
|
2017
Q4 | $13K | Hold |
18
| – | – | ﹤0.01% | 1215 |
|
|
2017
Q3 | $5K | Hold |
18
| – | – | ﹤0.01% | 1304 |
|
|
2017
Q2 | $4K | Hold |
18
| – | – | ﹤0.01% | 1279 |
|
|
2017
Q1 | $5K | Hold |
18
| – | – | ﹤0.01% | 1273 |
|
|
2016
Q4 | $10K | Hold |
18
| – | – | ﹤0.01% | 1172 |
|
|
2016
Q3 | $20K | Hold |
18
| – | – | ﹤0.01% | 1085 |
|
|
2016
Q2 | $19K | Hold |
18
| – | – | ﹤0.01% | 1120 |
|
|
2016
Q1 | $23K | Hold |
18
| – | – | ﹤0.01% | 1042 |
|
|
2015
Q4 | $44K | Hold |
18
| – | – | ﹤0.01% | 960 |
|
|
2015
Q3 | $19K | Hold |
18
| – | – | ﹤0.01% | 1098 |
|
|
2015
Q2 | $18K | Sell |
18
-5
| -22% | -$5.39K | ﹤0.01% | 1128 |
|
|
2015
Q1 | $23K | Sell |
23
-21
| -48% | -$69.3K | ﹤0.01% | 1098 |
|
|
2014
Q4 | $145K | Buy |
44
+39
| +780% | +$120K | ﹤0.01% | 760 |
|
|
2014
Q3 | $13K | Hold |
5
| – | – | ﹤0.01% | 1170 |
|
|
2014
Q2 | $18K | Buy |
+5
| New | +$18.8K | ﹤0.01% | 1119 |
|
|
2013
Q4 | – | Sell |
-4
| Closed | -$13K | – | 1421 |
|
|
2013
Q3 | $13K | Hold |
4
| – | – | ﹤0.01% | 1134 |
|
|
2013
Q2 | $10K | Buy |
+4
| New | +$12.9K | ﹤0.01% | 1162 |
|
Other funds holding NBSE
First Manhattan's NBSE Position: Q2 2024 in Review
First Manhattan sold out of NeuBase Therapeutics, Inc. Common Stock (NBSE) in Q2 2024, closing a stake of 353 shares — an estimated $158 sold.
First Manhattan first reported a position in NBSE in Q2 2013 and held it in 33 quarters. The position peaked at $145K in Q4 2014. 3 funds tracked by Wall St. Rank hold NBSE as of Q2 2024.
- First Manhattan reported no remaining NeuBase Therapeutics, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
- First Manhattan sold 353 NeuBase Therapeutics, Inc. Common Stock shares in Q2 2024, an estimated $158.
- First Manhattan first reported a position in NeuBase Therapeutics, Inc. Common Stock in Q2 2013 and held it in 33 quarters.
- First Manhattan's NeuBase Therapeutics, Inc. Common Stock position peaked at $145K in Q4 2014.
- 3 funds tracked by Wall St. Rank held NeuBase Therapeutics, Inc. Common Stock as of Q2 2024.
Based on First Manhattan's 13F filing for Q2 2024, filed 14 Aug 2024.